Grufity logoGrufity logo
StocksFundsSearch FilingsAPI

Amgen Inc Stock Research

AMGN

268.98USD-0.06(-0.02%)Market Closed
Watchlist

Market Summary

USD268.98-0.06
Market Closed
-0.02%

AMGN Stock Price

AMGN RSI Chart

AMGN Valuation

Market Cap

143.9B

Price/Earnings (Trailing)

18.03

Price/Sales (Trailing)

5.41

EV/EBITDA

7.4

Price/Free Cashflow

14.86

AMGN Price/Sales (Trailing)

AMGN Profitability

EBT Margin

34.80%

Return on Equity

148.04%

Return on Assets

8.92%

Free Cashflow Yield

6.73%

AMGN Fundamentals

AMGN Revenue

Revenue (TTM)

26.6B

Revenue Y/Y

5.94%

Revenue Q/Q

14.43%

AMGN Earnings

Earnings (TTM)

8.0B

Earnings Y/Y

4.71%

Earnings Q/Q

-51.46%

Price Action

52 Week Range

211.71292.06
(Low)(High)

Last 7 days

-0.9%

Last 30 days

4.9%

Last 90 days

21.6%

Trailing 12 Months

20.9%

AMGN Financial Health

Current Ratio

3.14

AMGN Investor Care

Dividend Yield

3.13%

Dividend/Share (TTM)

7.76

Buy Backs (1Y)

0.02%

Diluted EPS (TTM)

14.83

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales

Latest Insider Trading transactions for AMGN

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-08-10
Gordon Murdo
sold
-2,508,310
262
-9,558
evp, global commercial ops
2023-08-08
ISHRAK OMAR
acquired
-
-
124
-
2023-08-08
Drake Michael V
acquired
-
-
124
-
2023-08-08
HOLLEY CHARLES M
acquired
-
-
153
-
2023-07-31
Grygiel Nancy A.
sold (taxes)
-266,862
236
-1,129
svp & cco
2023-05-19
Kullman Ellen Jamison
acquired
-
-
939
-
2023-05-19
ISHRAK OMAR
acquired
-
-
939
-
2023-05-19
SUGAR RONALD D
acquired
-
-
939
-
2023-05-19
Garland Greg C.
acquired
-
-
939
-
2023-05-19
Austin Wanda M
acquired
-
-
939
-

1–10 of 50

Which funds bought or sold AMGN recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-09-26
BROOKFIELD Corp /ON/
reduced
-53.21
-332,943
250,883
-%
2023-09-26
M Holdings Securities, Inc.
sold off
-100
-545,000
-
-%
2023-09-21
Baystate Wealth Management LLC
added
3.64
-21,774
429,772
0.04%
2023-09-21
Jefferies Group LLC
added
3,672
16,526,300
17,013,200
0.14%
2023-09-20
BARCLAYS PLC
added
111
181,867,000
375,254,000
0.24%
2023-09-18
CAPE ANN SAVINGS BANK
new
-
213,361
213,361
0.14%
2023-09-14
IMS Capital Management
added
66.11
295,007
856,396
0.48%
2023-09-14
Proquility Private Wealth Partners, LLC
added
0.08
-70,654
804,934
0.32%
2023-09-13
CGC Financial Services, LLC
new
-
11,101
11,101
0.01%
2023-09-12
Farther Finance Advisors, LLC
added
74.29
163,904
436,566
0.10%

1–10 of 43

Latest Funds Activity

Are funds buying AMGN calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own AMGN
No. of Funds

Schedule 13G FIlings of Amgen

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 09, 2023
vanguard group inc
9.01%
48,065,139
SC 13G/A
Feb 07, 2023
blackrock inc.
9.1%
48,513,079
SC 13G/A
Feb 06, 2023
state street corp
5.58%
29,760,088
SC 13G/A
Feb 11, 2022
capital research global investors
3.9%
22,157,906
SC 13G/A
Feb 10, 2022
state street corp
5.37%
30,221,708
SC 13G/A
Feb 09, 2022
vanguard group inc
8.28%
46,661,009
SC 13G/A
Feb 01, 2022
blackrock inc.
8.9%
50,046,345
SC 13G/A
Feb 16, 2021
capital research global investors
5.5%
31,762,327
SC 13G/A
Feb 10, 2021
vanguard group inc
8.11%
47,227,229
SC 13G/A
Feb 05, 2021
state street corp
5.17%
30,113,284
SC 13G

Recent SEC filings of Amgen

View All Filings
Date Filed Form Type Document
Sep 27, 2023
SC 13D
13D - Major Acquisition
Sep 19, 2023
4
Insider Trading
Sep 14, 2023
3
Insider Trading
Sep 12, 2023
8-K
Current Report
Sep 05, 2023
8-K
Current Report
Sep 01, 2023
8-K
Current Report
Aug 21, 2023
3
Insider Trading
Aug 11, 2023
4
Insider Trading
Aug 10, 2023
4
Insider Trading
Aug 10, 2023
4
Insider Trading

AMGN Fair Value

Loading...

Peers (Alternatives to Amgen)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
143.9B
26.6B
4.85% 20.90%
18.03
5.41
0.75% 21.34%
94.2B
27.4B
-1.93% 22.79%
17.18
3.44
-0.48% 32.56%
37.9B
10.7B
-12.64% -18.65%
31.39
3.56
-53.67% -91.41%
37.3B
10.0B
-2.84% 30.20%
13.98
3.74
-6.23% 29.40%
MID-CAP
11.3B
1.7B
8.03% 13.91%
63.88
6.74
29.01% 1345.90%
4.3B
-
-8.13% 165.26%
-7.28
48.33
54.84% -12.96%
3.0B
-
-5.45% -21.11%
-23.04
37.44
122.90% 54.78%
1.9B
80.2M
3.54% -49.89%
-5.78
23.59
42.17% -39.82%
SMALL-CAP
1.4B
121.2M
-13.83% -27.58%
-4.86
11.52
-70.36% -531.73%
979.0M
15.3M
-20.35% -0.54%
-5.39
63.94
1090.59% -36.57%
678.1M
1.6B
-13.89% -64.12%
-1.16
0.42
23.74% 60.24%
206.9M
-
-21.05% -90.40%
-0.98
1.51
116.83% 16.61%
109.6M
2.1M
-12.14% -66.77%
-1.09
53.32
487.70% -8.66%
104.5M
-
-28.14% -88.04%
-0.53
0.43
113.96% -15.19%
3.6M
-
-8.13% -96.28%
-0.05
3.21
- -129.46%

Amgen News

msnNOW
September's Shakeout: S&P 500, Nasdaq 100 See Just 13% Of ....
msnNOW,
10 hours ago
Proactive Investors USA
Investor's Business Daily
U.S News & World Report Money
7 Diabetes and Weight Loss Drug Stocks With Big Potential.
U.S News & World Report Money,
32 hours ago
Investor's Business Daily

Returns for AMGN

Cumulative Returns on AMGN

11.9%


10-Year Cumulative Returns

9.9%


7-Year Cumulative Returns

8.4%


5-Year Cumulative Returns

6.3%


3-Year Cumulative Returns

Risks for AMGN

What is the probability of a big loss on AMGN?

28.1%


Probability that Amgen stock will be more than 20% underwater in next one year

0%


Probability that Amgen stock will be more than 30% underwater in next one year.

0%


Probability that Amgen stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does AMGN drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Amgen was unfortunately bought at previous high price.

Drawdowns

Financials for Amgen

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Last 12 Months)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Revenue1.5%26,58226,19026,32326,33026,38426,31625,97925,76725,48425,16425,42424,98724,30123,96623,36223,39523,56223,75023,74723,31923,188
Costs and Expenses-0.7%17,08717,20316,75716,69017,02618,30618,34018,42418,06616,25116,28515,80815,09914,40913,68813,38713,70713,74113,48413,19312,946
  S&GA Expenses-0.6%5,4115,4445,4145,2675,2855,3425,3685,7165,7575,6685,7305,4705,3475,3125,1505,1965,2665,3595,3325,2005,077
EBITDA-100.0%-14,24312,16912,41312,11711,12411,29611,04611,15412,71612,99612,91412,60312,74412,633------
EBITDA Margin-100.0%-0.54*0.46*0.47*0.46*0.42*0.43*0.43*0.44*0.51*0.51*0.52*0.52*0.53*0.54*------
Interest Expenses25.6%2,0781,6541,4061,3261,2541,2071,1971,1801,1861,2011,2621,2451,2561,2921,2891,3401,3821,3971,3921,3721,342
Earnings Before Taxes0.9%9,1969,1137,3467,7297,4926,5196,7016,4476,4987,9708,1338,2398,3108,8449,1389,3409,1579,2409,5459,5749,861
EBT Margin-100.0%-0.35*0.28*0.29*0.28*0.25*0.26*0.25*0.25*0.32*0.32*0.33*0.34*0.37*0.39*------
Net Income0.8%7,9797,9176,5526,8356,5765,7235,8935,6095,7467,0857,2647,3527,2997,6757,8428,0677,9588,0758,3942,2022,364
Net Income Margin-100.0%-0.30*0.25*0.26*0.25*0.22*0.23*0.22*0.23*0.28*0.29*0.29*0.30*0.32*0.34*------
Free Cashflow-100.0%-7,5318,7858,9978,3558,4178,3817,8408,8979,8359,88910,23510,2098,7958,532------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Assets1.7%90,26988,72065,12163,70059,29459,19661,16564,99359,77362,53962,94864,63765,01161,66959,70759,53559,37363,99766,41667,33367,684
  Current Assets6.0%47,38044,70322,18624,06219,32218,52019,38524,38019,09921,29921,14422,66122,89518,81318,44031,05130,74635,15137,61838,32037,970
    Cash Equivalents8.5%34,24831,5607,6299,5025,2036,5287,98911,9696,6306,1126,2669,0879,1457,6876,03711,4155,5257,3586,94511,95610,131
  Inventory-0.7%4,9785,0114,9304,7574,5544,4114,0864,1524,1154,0173,8933,9423,8403,6823,5843,2433,1763,0162,9403,0173,063
  Net PPE1.3%5,5325,4605,4275,1885,1585,1425,1844,9824,9064,8554,8894,8164,8434,8794,9284,9014,8824,8924,9584,8994,922
  Goodwill0%15,53115,53115,52914,84514,86514,89714,89014,66514,67614,67314,68914,67414,67814,68314,70314,70526.0014,69214,69914,68414,724
  Current Liabilities20.3%17,09714,21515,68714,33112,61812,88612,18414,84214,58512,86911,6539,95310,52311,82712,83510,73710,62212,70613,48812,43211,205
    LT Debt, Current159.8%2,1678341,5911,54381784487.004,2884,3241,55691.0091.0091.001,8402,9532,0492,8163,7054,4195,0774,288
    LT Debt, Non Current-2.3%59,37760,76137,35437,16135,70536,01033,22233,29128,45831,12932,89534,19634,13330,00826,95027,74227,79829,31929,51029,35030,209
Shareholder's Equity26.8%6,7815,3483,6613,6532,4199166,7008,2178,2479,3349,40910,95910,6599,4859,67310,92710,79410,83212,50014,34914,909
  Retained Earnings5.1%-25,540-26,919-28,622-28,066-28,252-29,568-24,600-22,964-22,762-21,639-21,408-19,851-20,168-21,378-21,330-20,136-20,054-19,895-17,977-15,987-15,266
Shares Outstanding0.1%535534534534535548558567573577578585588590591599607622630645656
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Last 12 Months)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Cashflow From Operations25.3%10,8008,6219,7219,8809,3209,3219,2618,6069,55610,46710,49710,85810,8679,4399,1509,8309,72610,41411,29611,11411,295
  Share Based Compensation---401---341---330---308---311309320
Cashflow From Investing43.3%-2,593-4,575-6,044-2,801-2,461941733-421-2,122-5,490-5,401-9,980-2,9801,9245,7097,0352,7952,98814,33918,89815,790
Cashflow From Financing-0.7%20,83820,986-4,037-9,546-8,286-9,846-8,271-5,303-9,949-6,552-4,867-3,206-4,267-11,034-15,767-17,406-17,127-15,785-22,490-21,056-19,583
  Dividend Payments2.4%4,3544,2534,1964,1464,1074,0774,0133,9553,8923,8263,7553,6833,6153,5533,5093,4893,4723,4573,5073,5013,488
  Buy Backs-100.0%-50.006,3607,8038,87210,4144,9754,7314,4143,4133,4863,3703,7885,5467,7028,6749,21710,05817,79416,47915,575

AMGN Income Statement

2023-06-30
Condensed Consolidated Statements of Income - USD ($)
shares in Millions, $ in Millions
3 Months Ended6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Revenues:    
Total revenues$ 6,986$ 6,594$ 13,091$ 12,832
Operating expenses:    
Cost of sales1,8131,5103,5333,071
Research and development1,1131,0392,1711,998
Selling, general and administrative1,2941,3272,5522,555
Other82542230532
Total operating expenses4,3024,4188,4868,156
Operating income2,6842,1764,6054,676
Interest expense, net(752)(328)(1,295)(623)
Other (expense) income, net(318)(317)1,746(847)
Income before income taxes1,6141,5315,0563,206
Provision for income taxes235214836413
Net income$ 1,379$ 1,317$ 4,220$ 2,793
Earnings per share:    
Basic (in usd per share)$ 2.58$ 2.46$ 7.90$ 5.16
Diluted (in usd per share)$ 2.57$ 2.45$ 7.86$ 5.13
Shares used in calculation of earnings per share:    
Basic (in shares)535535534541
Diluted (in shares)537537537544
Product sales    
Revenues:    
Total revenues$ 6,683$ 6,281$ 12,529$ 12,012
Other revenues    
Revenues:    
Total revenues$ 303$ 313$ 562$ 820

AMGN Balance Sheet

2023-06-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Millions
Jun. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 34,248$ 7,629
Marketable securities01,676
Trade receivables, net5,8305,563
Inventories4,9784,930
Other current assets2,3242,388
Total current assets47,38022,186
Property, plant and equipment, net5,5325,427
Intangible assets, net14,63316,080
Goodwill15,53115,529
Other noncurrent assets7,1935,899
Total assets90,26965,121
Current liabilities:  
Accounts payable1,2121,572
Accrued liabilities13,71812,524
Current portion of long-term debt2,1671,591
Total current liabilities17,09715,687
Long-term debt59,37737,354
Long-term tax liabilities4,4785,757
Other noncurrent liabilities2,5362,662
Contingencies and commitments
Stockholders’ equity:  
Common stock and additional paid-in capital; $0.0001 par value; 2,750.0 shares authorized; outstanding—534.9 shares in 2023 and 534.0 shares in 202232,60132,514
Accumulated deficit(25,540)(28,622)
Accumulated other comprehensive loss(280)(231)
Total stockholders’ equity6,7813,661
Total liabilities and stockholders’ equity$ 90,269$ 65,121
Robert A. Bradway
24200
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.